Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Intravenous immunoglobulin.

R J Wedgewood

    Clinical Immunology and Immunopathology
    |July 1, 1986
    PubMed
    Summary

    Intravenous immunoglobulin (IVIG) is a safe and effective treatment for immunodeficient patients, offering significant benefits that outweigh risks. Frequent IVIG infusions via home programs maintain normal serum levels, improving patient care.

    Related Concept Videos

    You might also read

    Related Articles

    Articles linked to this work by shared authors, journal, and citation graph.

    Sort by
    Same author

    Adenosine deaminase activity in lymphocytes.

    British journal of haematology·1977
    Same author

    The emergence of tetracycline resistance in Shigellae.

    The Journal of pediatrics·1962
    See all related articles

    Area of Science:

    • Immunology
    • Hematology
    • Pharmacology

    Background:

    • Immunoglobulin preparations for intravenous use mark a significant advancement in treating immunodeficient patients.
    • Current data demonstrate that the benefits of IVIG in patients with humoral immunodeficiency significantly outweigh the administration risks.

    Purpose of the Study:

    • To evaluate the efficacy and safety of intravenous immunoglobulin (IVIG) preparations.
    • To highlight IVIG as a potential treatment of choice for immunodeficient patients requiring immunoglobulin replacement therapy.

    Main Methods:

    • Review of clinical experience and published data on IVIG use in immunodeficient patients.
    • Analysis of the benefits versus risks associated with IVIG administration.
    • Discussion of home infusion programs for maintaining therapeutic serum immunoglobulin levels.

    Main Results:

    • IVIG is considered safe, acceptable, and efficacious for treating immunodeficient patients.
    • Frequent IVIG infusions, facilitated by home infusion programs, effectively maintain normal serum immunoglobulin levels.
    • Reports of non-A non-B hepatitis necessitate monitoring of liver function in patients receiving IVIG.

    Conclusions:

    • Intravenous immunoglobulin is a crucial therapeutic option for patients with immunodeficiencies.
    • Careful patient monitoring, including liver function tests, is recommended due to potential risks.
    • The widespread use of IVIG has greatly improved the management of primary immunodeficiency diseases.

    Related Experiment Videos